JPWO2021006267A1 - - Google Patents

Info

Publication number
JPWO2021006267A1
JPWO2021006267A1 JP2021530700A JP2021530700A JPWO2021006267A1 JP WO2021006267 A1 JPWO2021006267 A1 JP WO2021006267A1 JP 2021530700 A JP2021530700 A JP 2021530700A JP 2021530700 A JP2021530700 A JP 2021530700A JP WO2021006267 A1 JPWO2021006267 A1 JP WO2021006267A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530700A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021006267A1 publication Critical patent/JPWO2021006267A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021530700A 2019-07-08 2020-07-07 Pending JPWO2021006267A1 (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019127252 2019-07-08
PCT/JP2020/026541 WO2021006267A1 (ja) 2019-07-08 2020-07-07 ピラゾール誘導体の塩及びピラゾール誘導体の製剤

Publications (1)

Publication Number Publication Date
JPWO2021006267A1 true JPWO2021006267A1 (enrdf_load_stackoverflow) 2021-01-14

Family

ID=74115288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021530700A Pending JPWO2021006267A1 (enrdf_load_stackoverflow) 2019-07-08 2020-07-07

Country Status (3)

Country Link
JP (1) JPWO2021006267A1 (enrdf_load_stackoverflow)
TW (1) TW202116752A (enrdf_load_stackoverflow)
WO (1) WO2021006267A1 (enrdf_load_stackoverflow)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141228A1 (ja) * 2011-04-11 2012-10-18 株式会社ファルマエイト 新規ピラゾール誘導体
WO2014057772A1 (ja) * 2012-10-10 2014-04-17 株式会社ファルマエイト 新規ピラゾール誘導体
JP2014530875A (ja) * 2011-10-21 2014-11-20 シーチェイドファーマシューティカルズ,インコーポレーテッド 医薬組成物及びそれらの使用
JP2015500306A (ja) * 2011-12-13 2015-01-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高融点疎水性化合物のバイオアベイラビリティが向上した薬学的組成物
WO2016140219A1 (ja) * 2015-03-02 2016-09-09 武田薬品工業株式会社 ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法
JP2017500332A (ja) * 2013-12-23 2017-01-05 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 経口医薬組成物
JP2017503866A (ja) * 2014-12-23 2017-02-02 ハンミ ファーム. シーオー., エルティーディー. デュタステリドを含む自己乳化型薬物送達システムのための組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141228A1 (ja) * 2011-04-11 2012-10-18 株式会社ファルマエイト 新規ピラゾール誘導体
JP2014530875A (ja) * 2011-10-21 2014-11-20 シーチェイドファーマシューティカルズ,インコーポレーテッド 医薬組成物及びそれらの使用
JP2015500306A (ja) * 2011-12-13 2015-01-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高融点疎水性化合物のバイオアベイラビリティが向上した薬学的組成物
WO2014057772A1 (ja) * 2012-10-10 2014-04-17 株式会社ファルマエイト 新規ピラゾール誘導体
JP2017500332A (ja) * 2013-12-23 2017-01-05 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 経口医薬組成物
JP2017503866A (ja) * 2014-12-23 2017-02-02 ハンミ ファーム. シーオー., エルティーディー. デュタステリドを含む自己乳化型薬物送達システムのための組成物
WO2016140219A1 (ja) * 2015-03-02 2016-09-09 武田薬品工業株式会社 ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法

Also Published As

Publication number Publication date
WO2021006267A1 (ja) 2021-01-14
TW202116752A (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
BR112019017762A2 (enrdf_load_stackoverflow)
BR112021017339A2 (enrdf_load_stackoverflow)
BR112021018450A2 (enrdf_load_stackoverflow)
BR112021017637A2 (enrdf_load_stackoverflow)
BR112021017892A2 (enrdf_load_stackoverflow)
BR112021017939A2 (enrdf_load_stackoverflow)
BR112021008711A2 (enrdf_load_stackoverflow)
BR112021016821A2 (enrdf_load_stackoverflow)
BR112021018452A2 (enrdf_load_stackoverflow)
BR112021017234A2 (enrdf_load_stackoverflow)
BR112021015080A2 (enrdf_load_stackoverflow)
BR112021012348A2 (enrdf_load_stackoverflow)
BR112021017355A2 (enrdf_load_stackoverflow)
BR112021017173A2 (enrdf_load_stackoverflow)
BR112021018584A2 (enrdf_load_stackoverflow)
BR112021017310A2 (enrdf_load_stackoverflow)
BR112021016996A2 (enrdf_load_stackoverflow)
BR112021017083A2 (enrdf_load_stackoverflow)
BR112021013944A2 (enrdf_load_stackoverflow)
BR112021013128A2 (enrdf_load_stackoverflow)
BR112021018484A2 (enrdf_load_stackoverflow)
BR112021017949A2 (enrdf_load_stackoverflow)
BR112021017010A2 (enrdf_load_stackoverflow)
BR112021017983A2 (enrdf_load_stackoverflow)
BR112021016099A2 (enrdf_load_stackoverflow)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730